• Machine Learning Prediction of mRNA Lipid Nanoparticles

  2026-08-24

  The 2022 Acta Pharmaceutica Sinica B study developed a LightGBM model that predicted the performance of lipid nanoparticle formulations for mRNA vaccines from 325 formulation samples. Its value lies in combining data-driven formulation screening with animal validation and molecular dynamics, showing how computational prioritization can reduce reliance on empirical ionizable-lipid screening.

• RQ3025: Broad-Spectrum Bivalent mRNA Vaccine Evidence

  2026-08-23

  Lu et al. evaluated RQ3025, a bivalent mRNA vaccine engineered to incorporate spike mutations associated with SARS-CoV-2 evolution. Across several animal models, the candidate induced broad neutralizing activity, protected vaccinated rats against emerging variants, promoted a Th1-biased response, and showed no detected organ pathology after high-dose administration.

• Kanamycin Sulfate in RNA and Microbial Workflows

  2026-08-22

  Kanamycin Sulfate provides selective control during bacterial plasmid workflows, while a recent study shows how ultrafiltration can improve downstream circular RNA purity. This article connects antibiotic selection, template preparation, and RNA purification without treating kanamycin as a substitute for a dedicated RNA separation step.

• Kaempferol Activates NRF2 in Inflammatory Osteolysis

  2026-08-22

  A 2026 study identifies NRF2 as a direct molecular target of kaempferol and shows that NRF2/HO-1 activation suppresses oxidative stress, osteoclastogenesis, and inflammatory bone loss. By combining biophysical target validation with genetic and pharmacological inhibition, the work provides a mechanistic framework for studying NRF2 signaling pathway inhibition and activation in inflammatory osteolysis.

• CRISPRa Reveals Splice-Altering Variants in Fibroblasts

  2026-08-21

  Terkelsen et al. established an mRNA-delivered CRISPR activation strategy that induces expression of tissue-restricted genes in patient-derived skin fibroblasts. By combining dCas9-VPR activation with short- and long-read RNA analyses, the study provides a practical route for evaluating splice-altering variants that cannot be examined in conventional accessible tissues.

• EZ Cap Cy5 Firefly Luciferase mRNA Workflow

  2026-08-20

  Build a two-channel workflow that distinguishes mRNA uptake from productive protein expression. EZ Cap Cy5 Firefly Luciferase mRNA combines direct Cy5 tracking with luciferase output, making it useful for carrier screening, transfection optimization, and in vivo biodistribution studies.

• FAK Inhibitor 14: From Mechanism to Translation

  2026-08-20

  A translational framework for using FAK Inhibitor 14 to interrogate PARP1/FAK/COL5A1 signaling, EMT, adhesion, and migration in cholesterol-resistant ovarian cancer models.

• PKH26 Red Fluorescent Cell Linker Kit Guide

  2026-08-19

  The PKH26 Red Fluorescent Cell Linker Kit provides membrane-associated red fluorescence for tracking labeled cells and monitoring signal dilution during proliferation studies. It is intended for cell membrane lipid-region labeling in vitro or in vivo, not for intracellular targets or non-membrane-specific assays.

• Cytarabine (AraC) Workflow for Leukemia Research

  2026-08-19

  Build more informative Cytarabine assays by connecting DNA synthesis inhibition, deoxycytidine kinase activation, and apoptosis readouts. This workflow also shows how a recent viral cell-death study can sharpen assay selection without overstating Cytarabine’s role in necroptosis.

• Gamithromycin: PK/PD Workflows for Respiratory Research

  2026-08-18

  Gamithromycin supports more than a routine susceptibility screen: its serum-enhanced activity, lung-oriented distribution, and AUC24h/MIC relationship enable integrated respiratory infection workflows. This guide translates those features into practical in vitro, ex vivo, and animal-study designs for Pasteurella multocida and other veterinary respiratory pathogens.

• EdU Flow Cytometry Assay Kits (Cy5) in Wounds

  2026-08-18

  EdU Flow Cytometry Assay Kits (Cy5) provide direct S-phase DNA synthesis measurement for epithelial wound models. This guide connects copper-catalyzed azide-alkyne cycloaddition (CuAAC) chemistry with the DCPS–cell-cycle findings reported in diabetic foot ulcer research.

• ML385 and NRF2: A Translational Research Playbook

  2026-08-17

  A mechanistic and strategic guide to using ML385 as an NRF2 inhibitor for cancer therapeutic resistance, oxidative stress modulation, and pathway validation beyond conventional product-page claims.

• DiscoveryProbe FDA-approved Drug Library: Stress Screens

  2026-08-17

  Use a clinically annotated compound set to connect proteotoxic-stress phenotypes with actionable signaling hypotheses. This workflow combines scalable primary screening, orthogonal ROS/JNK and CREB assays, and translational follow-up for drug repositioning screening and disease-model discovery.

• RP3-340N1.2, IL-6, and NSCLC Progression

  2026-08-16

  A 2026 BioCell study identifies the lncRNA RP3-340N1.2 as a post-transcriptional regulator of IL-6 mRNA stability in non-small cell lung cancer. Its knockdown enhanced ZC3H12A-mediated IL-6 mRNA degradation, reducing tumor-cell proliferation, migration, and tumor-associated macrophage polarization in cellular and conditioned-medium models.

• LDH Cytotoxicity Assay Kit: Practical Workflow

  2026-08-15

  The LDH Cytotoxicity Assay Kit provides a colorimetric approach to cell cytotoxicity measurement by detecting LDH released into culture medium after membrane damage. It is appropriate for comparative cell damage quantification and viability workflows, but it should not be used alone to identify apoptosis, establish a death mechanism, or replace orthogonal validation.

7865 records 1/525 page Next 12345 下5页 Last page